

CADUS PHARMACEUTICAL CORP
Form SC 13D/A
May 15, 2002

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 13D
(Rule 13d-101)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)**

(AMENDMENT NO. 5)¹

Cadus Pharmaceutical Corporation

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

127639102

(CUSIP Number)

**Sandra Leung
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
(212) 546-4000**

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

December 6, 2001

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

(Continued on following pages)

(Page 1 of 12)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the

Act (however, see the Notes).

SCHEDULE 13D

CUSIP NO. 127639102

1. Names of Reporting Persons, S.S. or I.R.S. Identification Nos. of above persons.

BRISTOL-MYERS SQUIBB COMPANY

I.R.S. Employer Identification Number 22-079-0350

2. Check the Appropriate Box if a Member of a Group

- (a)
- (b)

3. SEC Use Only

4. Source of Funds (See Instructions)

WC

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

Delaware

7. Sole Voting Power

1,232,500

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY

8. Shared Voting Power

0

EACH
REPORTING
PERSON
WITH

9. Sole Dispositive Power

1,232,500

10. Shared Dispositive Power

0

11. Aggregate Amount Beneficially Owned by Each Reporting Person

1,232,500

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares

13. Percent of Class Represented by Amount in Row (11)

9.4%

14. Type of Reporting Person

CO

This Amendment No. 5 is being filed to amend Items 2 and 5 of this Schedule 13D.

Item 1. *Security and Issuer.*

The class of equity securities to which this Statement relates is the Common Stock, par value \$0.01 per share (the *Common Stock*), of Cadus Pharmaceutical Corporation, a Delaware corporation (the *Issuer*), which has its principal executive offices at 767 Fifth Avenue, New York, NY 10153.

Item 2. *Identity and Background.*

This Amendment is being filed by Bristol-Myers Squibb Company, a Delaware corporation (the *Company*). The Company conducts its principal business and maintains its principal office at 345 Park Avenue, New York, NY 10154. The Company is a worldwide pharmaceutical and related health care products company.

The name, business address, present principal occupation or employment and citizenship of each executive officer and director of the Company is set forth on Schedule A which is incorporated herein by reference.

During the past five years, neither the Company nor, to the best knowledge of the Company, any of its executive officers or directors (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. *Source and Amount of Funds or Other Consideration.*

In July 1994, the Issuer and the Company entered into a research collaboration, whereby the Company agreed to make an initial equity investment of \$12,500,000 in the Issuer's Series B Preferred Stock. The Company made an additional equity investment of \$5,000,000 in the Issuer's Series B Preferred Stock in September 1995 upon the Issuer achieving a research milestone. Both equity investments came out of the working capital of the Company.

On July 17, 1996, the Issuer completed an initial public offering of its Common Stock with a per share offering price of \$7.00. The Company made an additional equity investment of \$2,500,000, acquiring 355,000 shares of Common Stock. The purchase price for this investment came out of the working capital of the Company.

Item 4. Purpose of Transaction.

The Company acquired the Common Stock of the Issuer for the purpose of making an investment in the Issuer and not with the view to, or for resale in connection with, any distribution thereof. The Common Stock of the Issuer was initially acquired in connection with a research collaboration between the Company and the Issuer which expired in July 1999.

The Company and the Issuer are parties to a letter agreement (the Letter Agreement) concerning the Company's shares of the Common Stock. Such Letter Agreement is filed as an exhibit hereto and is incorporated herein by reference. The Letter Agreement includes certain notice requirements and transfer restrictions with respect to the Company's shares of the Common Stock. Subject to market conditions and the Letter Agreement, the Company may, in its sole discretion, sell all or a portion of its shares of Common Stock from time to time in open market transactions or otherwise.

Item 5. Interest in Securities of the Issuer.

To the best knowledge of the Company, as of May 13, 2002, the Company is the beneficial owner of 1,232,500 shares of Common Stock of the Issuer or approximately 9.4% of the Common Stock of the Issuer currently outstanding. The Company has the sole power to vote and dispose of all the shares of the Common Stock of the Issuer that it owns.

Except as set forth in this Item 5 and on Schedule B attached hereto which is incorporated herein by reference, neither the Company nor, to the best knowledge of the Company, any of its officers or directors owns any shares of Common Stock.

Except as set forth in Item 3 and on Schedule B attached hereto which is incorporated herein by reference, neither the Company nor, to the best knowledge of the Company, any of its executive officers or directors has effected any transaction in shares of Common Stock during the past sixty (60) days.

Item 6. *Contracts, Arrangements, Understanding or Relationships With Respect to Securities of the Issuer.*

The Preferred Stock Purchase Agreement, together with First Amendment thereto, filed as an exhibit hereto is incorporated herein by reference. Except as set forth in such Agreement or the Letter Agreement, neither the Company nor, to the best knowledge of the Company, any of its officers or directors have entered into any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to the Common Stock of the Issuer.

Item 7. *Material to be Filed as Exhibits.*

1. Preferred Stock Purchase Agreement dated as of July 26, 1994 between Issuer and the Company concerning Series B Preferred Stock, together with the First Amendment thereto dated as of October 31, 1995 (incorporated herein by reference to Exhibit No. 10.8 to Registration Statement No. 333-4441 on Form S-1).
2. Letter Agreement dated March 23, 1999 between the Issuer and the Company (incorporated herein by reference to Exhibit No. 2 to Amendment No. 2 to this Schedule 13D).

CUSIP No. 127639102

SCHEDULE 13D

Page 6 of 12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: May 15, 2002

BRISTOL-MYERS SQUIBB COMPANY

By:

/s/ SANDRA LEUNG

Sandra Leung
Corporate Secretary

SCHEDULE A

The following information sets forth the name, citizenship, business address and present principal occupation of each of the directors and executive officers of the Company. Except as set forth below, each of the directors and executive officers of the Company is a citizen of the United States. Each of the Company's executive officer's business address is 345 Park Avenue, New York, New York 10154, unless otherwise indicated.

Directors of Bristol-Myers Squibb Company**Name and Business Address****Present Principal Occupation**

Peter R. Dolan
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154

Chairman and Chief Executive Officer

Robert E. Allen
AT&T Corp
180 Park Avenue
Room 1E38
Florham Park, NJ 07932

Retired Chairman and Chief Executive Officer

Lewis B. Campbell
Textron Inc.
40 Westminister Street
Providence, RI 02903-2596

Chairman and Chief Executive Officer

Vance D. Coffman
Lockheed Martin Corporation
6801 Rockledge Drive
Bethesda, MD 20817

Chairman and Chief Executive Officer

Ellen V. Futter
American Museum of Natural History
Central Park West at 79th Street
New York, NY 10024

President

CUSIP No. 127639102

SCHEDULE 13D

Page 8 of 12

Name and Business Address**Present Principal Occupation**

Louis V. Gerstner, Jr.
IBM Corporation
New Orchard Road
Armonk, NY 10504

Chairman and Chief Executive Officer

Laurie H. Glimcher, M.D.
Harvard Medical School and
Harvard School of Public Health
Dept. of Immunology and Infectious Diseases
651 Huntington Avenue, FXB-2
Boston, MA 02115

Irene Heinz Given Professor of Immunology

Leif Johansson
AB Volvo
SE-40508
Goteborg, Sweden
Citizen of Sweden

President and Chief Executive Officer

James D. Robinson III
RRE Investors
126 East 56th Street, 22nd Floor
New York, NY 10022

Chairman and Chief Executive Officer

Louis W. Sullivan, M.D.
Morehouse School of Medicine
720 Westview Drive, S.W.
Atlanta, GA 30310-1495

President

Executive Officers of Bristol-Myers Squibb Company**Name****Present Principal Occupation**

Peter R. Dolan

Chairman and Chief Executive Officer

Harrison M. Bains, Jr.

Acting Chief Financial Officer and Vice President,
Tax & Treasury

Stephen E. Bear

Senior Vice President, Human Resources

| <u>Name</u> | <u>Present Principal Occupation</u> |
|---------------------------|---|
| Andrew G. Bodnar, M.D. | Senior Vice President, Medical and External Affairs |
| Wendy L. Dixon | Chief Marketing Officer and President, Global Marketing |
| Donald J. Hayden, Jr. | Executive Vice President and President, North American Medicines |
| Tamar D. Howson | Senior Vice President, Corporate Development |
| George P. Kooluris | Senior Vice President, Corporate Development |
| Sandra Leung | Corporate Secretary and Head of the Office of Corporate Conduct |
| John L. McGoldrick | Executive Vice President and General Counsel |
| Dean J. Mitchell | President, U.S. Primary Care |
| Peter S. Ringrose, Ph.D. | Chief Scientific Officer and President, Pharmaceutical Research Institute |
| Elliot Sigal, M.D., Ph.D. | Senior Vice President, Global Clinical & Pharmaceutical Development. |
| Curtis L. Tomlin | Vice President and Controller |

SCHEDULE B**Shares of Common Stock Owned**

None.

Transactions in Shares of Common Stock

Sales on the open market by the Company of the Issuer's Common Stock from the date that was 60 days prior to the date of event requiring the filing of this Statement through May 13, 2002 are described below:

| <u>Date</u> | <u>Number of Shares</u> | <u>Price Per Share</u> |
|-------------|-------------------------|------------------------|
| 10/10/01 | 3,000 | \$1.00 |
| 11/29/01 | 5,000 | \$1.00 |
| 11/30/01 | 26,000 | \$1.01 |
| 12/04/01 | 3,000 | \$1.00 |
| 12/06/01 | 7,000 | \$1.00 |
| 12/11/01 | 5,000 | \$1.00 |
| 12/13/01 | 5,000 | \$1.00 |
| 12/14/01 | 18,000 | \$1.00 |
| 12/17/01 | 12,000 | \$1.02 |
| 12/18/01 | 4,000 | \$1.02 |
| 12/19/01 | 2,000 | \$1.01 |
| 12/21/01 | 1,000 | \$1.06 |
| 12/24/01 | 4,000 | \$1.12 |
| 12/26/01 | 4,500 | \$1.17 |
| 12/27/01 | 6,000 | \$1.16 |
| 12/28/01 | 2,000 | \$1.15 |
| 12/31/01 | 5,500 | \$1.16 |
| 01/02/02 | 15,000 | \$1.22 |
| 01/03/02 | 4,000 | \$1.26 |
| 01/04/02 | 2,000 | \$1.30 |
| 01/09/02 | 26,000 | \$1.34 |
| 01/10/02 | 10,000 | \$1.34 |

Transactions in Shares of Common Stock (continued)

| | | |
|----------|--------|--------|
| 01/11/02 | 3,000 | \$1.35 |
| 01/14/02 | 21,000 | \$1.37 |
| 01/15/02 | 6,000 | \$1.38 |
| 01/16/02 | 11,000 | \$1.41 |
| 01/17/02 | 6,000 | \$1.37 |
| 01/18/02 | 22,000 | \$1.22 |
| 01/22/02 | 6,000 | \$1.14 |
| 01/23/02 | 10,000 | \$1.16 |
| 01/24/02 | 10,000 | \$1.19 |
| 01/25/02 | 24,000 | \$1.24 |
| 01/30/02 | 21,000 | \$1.16 |
| 01/31/02 | 15,000 | \$1.18 |
| 02/04/02 | 28,000 | \$1.17 |
| 02/06/02 | 10,000 | \$1.18 |
| 02/08/02 | 3,000 | \$1.16 |
| 02/19/02 | 5,000 | \$1.17 |
| 02/25/02 | 18,673 | \$1.12 |
| 02/28/02 | 5,000 | \$1.14 |
| 03/07/02 | 2,000 | \$1.16 |
| 03/08/02 | 5,000 | \$1.17 |
| 03/11/02 | 4,000 | \$1.18 |
| 03/12/02 | 2,000 | \$1.19 |
| 03/13/02 | 2,500 | \$1.22 |
| 03/18/02 | 13,000 | \$1.19 |
| 04/01/02 | 2,000 | \$1.19 |
| 04/22/02 | 22,000 | \$1.15 |
| 04/23/02 | 2,000 | \$1.17 |
| 04/26/02 | 60,000 | \$1.23 |
| 04/29/02 | 12,000 | \$1.24 |
| 04/30/02 | 6,000 | \$1.23 |
| 05/01/02 | 5,000 | \$1.23 |
| 05/06/02 | 37,000 | \$1.26 |
| 05/07/02 | 16,000 | \$1.27 |
| 05/10/02 | 13,000 | \$1.21 |

CUSIP No. 127639102

SCHEDULE 13D

EXHIBIT INDEX

| <u>Exhibit Number</u> | <u>Document</u> |
|----------------------------------|---|
| 1 | Preferred Stock Purchase Agreement dated as of July 26, 1994 between Cadus Pharmaceutical Corporation and Bristol-Myers Squibb Company, together with the First Amendment thereto dated as of October 31, 1995 (incorporated herein by reference to Exhibit No. 10.8 to Registration Statement No. 333-4441 on Form S-1). |
| 2 | Letter Agreement dated March 23, 1999 between the Issuer and the Company (incorporated herein by reference to Exhibit No. 2 to Amendment No. 2 to this Schedule 13D). |